**Name of journal:** **World Journal of Hepatology**

**ESPS Manuscript NO: 6055**

**Columns: REVIEW**

**Fatty liver in childhood**

Ozturk Y *et al*. Fatty Liver

Yesim Ozturk, Ozlem Bekem Soylu

**Yesim Ozturk,** Department of Pediatrics, Division of Pediatric Gastroenterology, Dokuz Eylul University School of Medicine, Inciralti, 35340 İzmir, Turkey

**Ozlem Bekem Soylu,** Hepatology and Nutrition Unit, Department of Paediatric Gastroenterology, Behcet Uz Children's Disease and Pediatric Surgery Training and Research Hospital, Alsancak, 35340 İzmir, Turkey

**Author contributions:** Ozturk Y collected data and wrote the manuscript; Ozturk Y and Soylu OB were also involved in writing and editing the manuscript.

**Correspondence to: Yesim Ozturk, MD, PhD, Professor,** Department of Pediatrics, Division of Pediatric Gastroenterology, Dokuz Eylul University School of Medicine, Inciralti, Cumhuriyet Blv No.144, 35340 İzmir, Turkey. yesimzaferozturk@gmail.com

**Telephone**: +90-232-4126106 **Fax**: +90-232-4126106

**Received:** September 30, 2013 **Revised:** November 26, 2013

**Accepted:** December 9, 2013

**Published online:**

**Abstract**

Fatty liver is a growing health problem worldwide. It might evolve to nonalcoholic steatohepatitis, cirrhosis and cause hepatocellular carcinoma. This disease, which increased because of feeding habits, changes in food contents and life style, impresses people since childhood. The most important risk factors are obesity and insulin resistance. Besides these factors gender, ethnicity, genetic predisposition and some medical problems are also important. Cirrhosis in children is rare but reported. Nonalcoholic fatty liver disease (NAFLD) has no specific symptom or sign, but should be considered in obese children. NAFLD does not have a proven treatment. Weight loss with family based treatments is the most acceptable management. Exercise and an applicable diet with low glycemic index and appropriate calorie intake are preferred. Drugs are promising but not sufficient in children for today.

© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key Words:** Nonalcoholic fatty liver disease; Non-alcoholic steatohepatitis; Children; Obesity; Metabolic syndrome; Insulin resistance; Chronic liver disease

**Core tip:** Nonalcoholic fatty liver disease (NAFLD) consists of steatosis in liver, steatohepatitis and cirrhosis. Histological type 2 pattern (macrovesicular steatosis with portal inflammation and/or fibrosis, generally without evidence of cellular injury or lobular inflammation) is seen in children different than adults. The most important risk factors are obesity, insulin resistance and also gender, ethnicity, genetic predisposition, some medical problems. Progression to cirrhosis in children is rare but possible. NAFLD does not have a proven treatment. Losing weight and increasing physical activity provide improvement in histological and biochemical findings in fatty liver. Drugs are used in specific situations. More research is needed for drug therapy.

Ozturk Y, Soylu OB. Fatty liver in childhood

**Available from:**

**DOI:**

**INTRODUCTION**

Fat is stored as triglyceride (TG) in human liver. Steatosis is defined as fat accumulation in hepatocytes and seen in many liver diseases[1-3].

Nonalcoholic fatty liver disease (NAFLD) defines the spectrum of histological changes in liver in which macrovesiculer steatosis is outstanding[3]. NAFLD includes simple hepatic steatosis due to obesity and/or insulin resistance, non-alcoholic steatohepatitis (NASH) and cirrhosis. Hepatosteatosis usually limits itself, but it may advance to NASH. NASH differs from simple steatosis by hepatocyte damage, inflammatory infiltrate and collagen deposition[4-6].

In many ways NASH pattern and characteristics differ between children and adults[7]. In adults common features are combination of macrovesicular steatosis with ballooning degeneration, lobular inflammation with or without pericellular fibrosis localized primarily in acinar zone 3 (type 1). Pediatric NASH is characterized by macrovesicular steatosis with portal inflammation and/or fibrosis, generally without evidence of cellular injury or lobular inflammation (Type 2). Type 1 and type 2 NASH are distinct subtypes of paediatric NAFLD associated with different clinical demographic and possible pathophysiological features. In children with NAFLD aged 2-18 years 51% is type 2 and 17% is type 1. In most of the children with extensive fibrosis type 2 pattern is demonstrated[8]. These children are younger and more obese with regard to children displaying type 1 pattern. Type 2 NASH is more common in boys than girls. Asian, Native American race and those of Hispanic ethnicity predominantly demonstrated type 2. Among children with type 2 NASH, it is not known whether the pattern evolves into more characteristically adult type 1 pattern as the children grow older[9].

There is an increase in NAFLD frequency in the last 30 years[1,8-11]. Nowadays NAFLD is the most common form of liver disease in children[7]. A chronic obesity associated condition, NAFLD can lead to cirrhosis and liver failure over time[8]. It is also an independent risk factor for cardiovascular disease and liver cancer[9]. The studies have demonstrated differences in NAFLD prevalence rates across race/ethnicity, gender, weight status[12-14].

**EPIDEMIOLOGY**

In developed countries hepatosteatosis is seen in 20%-30% of unselected population[15]. The prevalence of NAFLD in Hong Kong Chinese is 27.3%. Around 4% of patients with fatty liver in the community had advanced fibrosis as estimated by transient elastography[16].

Frequency of NASH is considered to be 2%-3%. It is reported that 10%-29% of NASH cases develop cirrhosis in 10 years[17]. Cirrhosis may progress to liver cancer. Hepatocellular carcinoma may occur in 4%-27% of the individuals with NASH-induced cirrhosis[18-20].

Since childhood obesity became epidemic in developed countries, NAFLD came out to be the most common reason of chronic liver disease in pediatrics[7].

In fact true NAFLD prevalence in children is unknown. A population based autopsy study reported that 13% of children and adolescents are affected with NAFLD, 23% of the subjects with NAFLD had evidence for steatohepatitis, whereas bridging fibrosis or cirrhosis was observed in 9% of the children with NASH. Overweight and obese children accounted for 81% of all of the cases of NAFLD. A male-to-female ratio of 2:1[7,20-23].

It is suggested that, NAFLD prevalence increases with age, with a mean age at diagnosis between 11 and 13 years[24]. This tendency is explained by adolescent hormonal changes, which result in an increase in serum insulin levels and fat accumulation in the liver[25,26].

# Obesity and insulin resistance is the most common risk factors for NAFLD. However, different amount of fat accumulation in individuals with similar adipose tissue suggests that other factors also are responsible. Gender, ethnicity, genetic predisposition are emphasized[27-35].

The prognosis of children with NAFLD is still unknown. Patients with simple steatosis may still develop NASH and fibrosis progression. It is reported that, weight reduction is associated with non-progressive disease in adult patients[28]. It is suggested that long term survival of NAFLD pediatric patients is shorter than non-affected patients[29].

**PATHOGENESIS**

Triglycerides are preferred as storage nutrients in cells to regulate the changes between intake and usage. Triglycerides supply high calorie. Additionally, because they are not dissolved in water, they might be stored intracellularly in high amounts without causing any colloidal or osmotic problem. Triglycerides are basic material stocks of adipocytes and are not accumulated in other cells except unusual situations. Steatosis in liver is not an adaptive process; indeed it may cause severe chronic problems[1].

Fat droplets should be seen in at least 5% of hepatocytes to be named as steatosis. Another definition is TG deposition in liver above 95th percentile or more than 55 mg per gram liver tissue in a healthy lean person[2].

Hepatosteatosis might be seen in two different types; macrovesicular and microvesicular. In macrovesicular steatosis one or few lipid droplets are present filling the total hepatocyte. These lipid droplets propel the nucleus to the edge. In microvesicular type multiple small lipid droplets are seen giving a foamy appearance[3].

Microvesicular steatosis might be seen in Reye syndrome, salicylate, sodium valproate or ethanol intake, fulminant hepatitis D, mitochondrial fatty acid beta oxidation defects and urea cycle disorders. In these disorders usually liver function tests are affected and patient is comatose. If the patient survives permanent damage will not occur in liver. Macrovesicular type occurs in alcoholic liver disease, obesity, diabetes, kwashiorkor, AIDS, total parenteral nutrition therapy, phosphorus intoxication and steroid treatment[3].

High concentration of serum saturated free fatty acids is important in pathogenesis of steatosis. This high concentration of saturated free fatty acids creates hepatotoxic impulse. Besides, esterification of these free fatty acids into TGs is a process of detoxification. The balance between TG deposition and removal is disrupted. There are three sources of fatty acids causing TG deposition in liver: from diet 15%, *de-novo* synthesis (carbohydrates from diet) 26% and adipose tissue-circulating 59%[1,5].

Twenty percent of the fat present in the systemic circulation (100 g/d) is taken by the liver. Daily intake of TGs from diet (approximately 20g/d) and free fatty acids from adipose tissue (approximately 20 g/d) enter liver as TG[1,36]. There is an increase in NAFLD frequency in the last 30 years. It is considered that this is due to changes in amount and content of food. Changes in food composition cause steatosis in liver. Generally carbohydrates and fructose play the most important role in this issue. Fructose influences the dietary carbons to move to liver and participate in lipogenesis. Despite glucose, fructose is taken from the systemic circulation almost totally. Fructose is phosphorylated at C1 instead of C6 and because of this it cannot be used in glycogen synthesis. Instead fructose is changed to glyceraldehyde-3-phosphate, which provides substrate for *de-novo* lipogenesis. Yearly fructose intake of the population is increasing day by day and consequently NAFLD incidence is rising[1,37]. As the adipose tissue increases in obesity, death receptors in adipose tissue and apoptosis pathway are activated. Increase in adipocyte death causes more macrophage migration. As a result insulin resistance and hepatosteatosis occur. Approaches blocking apoptosis of adipose cells are considered to improve complications related to obesity including NAFLD. Lipoapopitosis is related to AST/ALT > 1 and liver fibrosis[38-40].

Insulin stimulates fatty acid production while preventing glucose production in liver. As insulin resistance develops in liver, effect of insulin on preventing glucose production diminishes. However, the effect of insulin on stimulating fat synthesis in liver is preserved. When insulin level decreases with therapy, steatosis in liver decreases also. Additionally, high insulin levels increase hepatotoxicity by preventing FFA oxidation[41].

It is suggested that NAFLD pathogenesis is multifactorial with many factors affecting disease development and progression. The “multiple-hit” hypothesis is currently the established pathogenetic model[42]. At the onset, NAFLD is characterized by fat accumulation in the liver and insulin resistance, influenced by genetic susceptibility, epigenetic mechanisms, a sedentary lifestyle, and hypercaloric diets[43]. Hepatic fat accumulation leads to exacerbate insulin resistance by interfering with phosphorylation of insulin receptor substrates[44]. Free fatty acid accumulation and insulin resistance predispose the fatty liver including oxidative stress, inflammatory cytokines, stellate cells activation and mitochondrial disturbance, which lead to inflammation, necrosis and fibrosis[45]. A changing of gut microbiota and excess gut permeability increase liver exposure to gut-derived bacterial products in NAFLD. These products stimulate innate immune receptors, and triggers liver inflammation and fibrogenesis[46].

Hepatic progenitor cell activation is correlated with fibrosis and NASH progression[47]. Adiponectin, leptin, resistin, and tumour necrosis factor-alpha also related to be involved in the progression of steatosis to NASH. Adipocytes or inflammatory cells infiltrating the adipose tissue in insulin resistance are responsible for adipocytokine secretion. Leptin may activate hepatic stellate cells. The expansion of adipose tissue, especially visceral fat is associated with a decrease in the release of insulin-sensitizing and anti-inflammatory cytokines and an increase in the release of pro-inflammatory molecules[48]. Tumour necrosis factor-alpha and interleukine-6 levels are elevated in the liver and blood of NASH patients. These cytokines are involved in Kupffer and hepatic stellate cell activation in myofibroblasts[49]. NAFLD results from relationship between multiple organs, including adipose tissue, liver, gut and the pancreas[50,51].

**CLINICAL FINDINGS**

Most of the cases are asymptomatic, but nonspecific symptoms like abdominal pain may be present[30]. The most common admission reason is slightly elevated transaminases or coincidentally noticed hepatomegaly. Multiple diseases like Wilson’s disease, drug-induced liver injury, autoimmune hepatitis should be excluded before diagnosis of NAFLD[30,31].

Obesity is distinctive[7-15,31]. In adults 10%-75% of fatty liver is together with insulin resistant type 2 diabetes. Fatty liver is defined in poor regulated type 1 diabetes (Mauriac sendromu) in children. Children with typical NAFLD have insulin resistance with hyperinsulinemia but they are euglycemic. Type 2 diabetes mellitus is present in 5.5% of NASH cases[15,32]. Acanthosis nigricans, defined as hyperplasia of pigmented skin cells, is an important physical examination seen with insulin resistance. This can be found in more than 50% of children with NASH. Family story is important in NAFLD because familial clustering is common[33-35].

Obesity is reported especially after ALL chemotherapy, hypothalamic dysfunction or hypothalamic surgery. Even NAFLD progressing to cirrhosis is defined in these children. NAFLD is seen in Prader-Willi syndrome also. Besides these fatty liver may be seen concurrently with some inborn errors of metabolism and genetic diseases. Insulin resistance, obesity, type 2 DM and NAFLD progressing to cirrhosis may be seen in Alström. Liver fibrosis is reported in Turner’s syndrome. Also in lipodystrophy, cases are present with cirrhosis that had liver transplantation[35,52].

**LABORATORY FINDINGS**

In NAFLD serum aminotransferases are moderately high, ALT being higher than AST. Increase in AST and reversing of AST/ALT ratio in NAFLD predicts bad prognosis. Raised ALT and GGT levels, especially if they are within normal ranges, are found related to hepatic steatosis evaluated by USG or MRI. Therefore changing the normal ranges is being discussed. Serum GGT > 96.5 U/L is a marker of advanced fibrosis. Serum bilirubin levels are normal or near normal. Biochemical findings of cholestasis are not present[32-57]. Serum IgG and nonspecific tissue autoantibodies imply autoimmunity. Mostly the anti-smooth muscle antibody is positive at low titer[52-54].

The other markers synthesized in liver like sex hormone binding globulin, ferritin, plasminogen activating inhibitor-1 may be used in diagnosis of NAFLD[54]. Homocysteine level may increase in steatohepatitis. High hyaluronic acid levels is the most powerful independent marker of severe fibrosis and distinguishes steatosis and NASH[15,55-57]. Laminin and ELF (enhenced liver fibrosis) score may be used also. Low adiponectin with low adipokine is important in NASH diagnosis. A combination of serum adiponectin, homoeostasis model assessment of insulin resistance (HOMA-IR) and type IV collagen 7S, at cut-off limits of ≤ 4.0 μg/mL, ≥ 3.0 and ≥ 5.0 ng/mL respectively was shown to have a sensitivity of 94% and specificity of 74% for identifying early NASH[58]. Cut-off values of HOMA-IR for insulin resistance are higher than adults. When an obese patient loses weight, normal ALT decreases more and also a decrease in HOMA-IR occurs with insulin resistance.

Hypoadiponectinemia and high tumor necrosis factor-alpha levels were found related to the NAFLD[59-71]. However adiponectin and tumor necrosis factor-alpha gene polymorphism were not shown to be associated with NAFLD or significant fibrosis in Chinese people[72].

Urea, electrolytes, thyroid function tests, glucose, HbA1C, serum lipids should be controlled. Most common lipid disorder is hypertriglyceridemia. Autoantibodies, immunoglobulines, viral markers for hepatitis B, hepatitis C, Cytomegalvirus and Ebstein-Barr virus are important in excluding chronic liver diseases. Especially chronic hepatitis C, Wilson’s disease, cystic fibrosis and drug intoxication (*e.g.,* methotrexate) should be excluded[72].

Steatosis may be diagnosed by ultrasound, computed tomography or MRI scanning. Ultrasound, the cheapest option, has been reported to have a sensitivity of 89% and specificity of 93% for the identification of fatty liver[73]. Abdominal USG does not reflect changes in liver histology. It is not useful in distinguishing steatosis and NASH. Microvesicular steatosis is due to hereditary inborn errors of metabolism, urea cycle disorders and valproic acid toxicity, and it is more severe. USG with a good history taking and metabolic tests may be sufficient in diagnosis of microvesicular steatosis[15]. ALT and AST levels are not always parallel to histological state, therefore in children with risks USG should be performed even ALT and AST are normal[74,75].

# New non-invasive tests such as proton-magnetic resonance spectroscopy and transient elastography allow relatively accurate estimation of hepatic steatosis and fibrosis in the community[74-81].

Liver biopsy may be essential in diagnosis of NAFLD and distinguishing NASH from other disorders. In obese patients biopsy may be needed to differentiate NAFLD from hepatitis. Optimal timing for this is not certain. Some physicians delay biopsy for 3-6 mo, make the patient lose weight and perform biopsy if ALT is still high. In younger children and cases with acanthosis nigricans biopsy may be performed but there is no sufficient data for this[30,82].

**TREATMENT**

In childhood fatty liver does not have a proven treatment[83]. In a meta-analysis evaluating studies on adults, losing weight is reported to improve histological activity in NASH but > 50% of the patients could not reach the estimated weight[84,85]. In literature results of the studies about antioxidants in NASH therapy are conflicting and heterogeneous. In studies with pentoxifylline, telmisartan, L-carnitine and polyunsaturated fatty acids, it is stated that these agents may improve different parameters (radiology, biochemistry, histology) of NASH[86-88]. Vitamin E or metformin is not efficient in fatty liver in children[89].

As apoptosis is the key pathogenic mechanism in NAFLD, antiapoptotic agents are considered to be efficient in treatment. Studies are proceeding on chemical chaperons (glycerol, 4-phenyl butyric acid, TUDCA), PUFA (decreases ER stress and cell death in liver caused by saturated FFA), protease inhibitors (pan-caspase inhibitor Z-VAD-fmk, VX-166) and kinase inhibitors[11,90-93].

Drugs increasing insulin sensitivity are also studied in NASH. Indeed best management of insulin resistance is losing weight but drugs are used also. In pediatric NASH, 1000 mg/d metformin decreased ALT, in 40% ALT became normal, and in 90% steatosis in liver detected by MR spectroscopy decreased 23%. Metformin is effective on SREBP-1c and it is used in adulthood NASH. If evidence of childhood obesity and insulin resistance is present, it is useful and advised to be used. It is used in childhood type 2 diabetes, PCOS and Prader-Willi syndrome[92]. Thiazolidinedione is reported to improve steatosis and inflammation but cause severe weight gain[85].

Exercise, diet and bariatric surgery improve liver histology. Standard obesity surgery is not studied in children, and effect on NAFLD is not known. None of the drug therapies in children is efficient on NAFLD[9,66,71,95,96].

Multi-disciplinary management is needed in obesity treatment. Decrease in weight normalizes transaminases and liver histology. Most acceptable strategy is lowering weight gain and regular medium level exercise. For losing weight, diets with low glycemic index and realistic portions are helpful. Special diets bringing hyperinsulinism to minimal instead of standard low calorie diets are more effective in childhood obesity. Diets with low postglycemic index may be carried out longer than calorie restriction[96-98]. In management of obesity family based behavior therapies increase success. The other valuable factor is exercise because it decreases hyperinsulinemia[99-101].

**CONCLUSION**

Fatty liver is a growing health problem worldwide. It might evolve to nonalcoholic steatohepatitis, cirrhosis and cause hepatocellular carcinoma. There are two distinct subtypes of paediatric NAFLD associated with different clinical, demographic and possible pathophysiological features. In children with NAFLD aged 2-18 years, 51% is type 2 and 17% is type 1. The most important risk factors for NAFLD are obesity and insulin resistance. In general, NAFLD has no specific symptom or sign, but should be considered in obese children. The most common admission reason is slightly elevated transaminases or coincidentally noticed hepatomegaly. In NAFLD serum aminotransferases are moderately high, ALT being higher than AST. Increase in AST and reversing of AST/ALT ratio in NAFLD predicts bad prognosis. Progression to cirrhosis in children is rare but possible. The treatment of this disease is not certain. It is demonstrated that decrease in weight normalizes transaminases and liver histology. Therefore, weight loss with regular medium level exercise and an applicable diet with low glycemic index and appropriate calorie intake are preferred. Drugs are promising but not sufficient in children for today.

In conclusion, since childhood obesity became epidemic in developed countries, NAFLD came out to be the most common reason of chronic liver disease in pediatrics. Therefore it should be taken in consideration in obese children. After excluding other diseases multi-disciplinary management should be started for weight loss.

**REFERENCES**

1 **Cohen JC**, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. *Science* 2011; **332**: 1519-1523 [PMID: 21700865 DOI: 10.1126/science.1204265]

2 **Szczepaniak LS**, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. *Am J Physiol Endocrinol Metab* 2005; **288**: E462-E468 [PMID: 15339742 DOI: 10.1152/ajpendo.00064.2004]

3 **Ludwig J**, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc* 1980; **55**: 434-438 [PMID: 7382552]

4 **Sanyal AJ**. Nonalcholic fatty liver disease. In: Yamada T (ed). Textbook of Gastroenterology (5th ed) Oxford: Blackwell Publishing Ltd, 2009: 2274-2300

5 **Donnelly KL**, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. *J Clin Invest* 2005; **115**: 1343-1351 [PMID: 15864352]

6 **Ko JS**, Yoon JM, Yang HR, Myung JK, Kim H, Kang GH, Cheon JE, Seo JK. Clinical and histological features of nonalcoholic fatty liver disease in children. *Dig Dis Sci* 2009; **54**: 2225-2230 [PMID: 19697129 DOI: 10.1007/s10620-009-0949-3]

7 **Schwimmer JB**, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. *Pediatrics* 2006; **118**: 1388-1393 [PMID: 17015527 DOI: 10.1542/peds.2006-1212]

8 **Schwimmer JB**, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, Lavine JE. Histopathology of pediatric nonalcoholic fatty liver disease. *Hepatology* 2005; **42**: 641-649 [PMID: 16116629 DOI: 10.1002/hep.20842]

9 **Barshop NJ**, Sirlin CB, Schwimmer JB, Lavine JE. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2008; **28**: 13-24 [PMID: 18397387 DOI: 10.1111/j.1365-2036.2008.03703]

10 **Kopec KL**, Burns D. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. *Nutr Clin Pract* 2011; **26**: 565-576 [DOI: 10.1177/0884533611419668]

11 **Dunn W**, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, Schwimmer JB. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. *Am J Gastroenterol* 2008; **103**: 2263-2271 [PMID: 18684196 DOI: 10.1111/j.1572-0241.2008.02034]

12 **Quirós-Tejeira RE**, Rivera CA, Ziba TT, Mehta N, Smith CW, Butte NF. Risk for nonalcoholic fatty liver disease in Hispanic youth with BMI & gt; or =95th percentile. *J Pediatr Gastroenterol Nutr* 2007; **44**: 228-236 [PMID: 17255837 DOI: 10.1097/MPG.0b013e31802d4acc]

13 **Schwimmer JB**, Dunn W, Norman GJ, Pardee PE, Middleton MS, Kerkar N, Sirlin CB. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. *Gastroenterology* 2010; **138**: 1357-1364, 1364.e1-2 [DOI: 10.1053/j.gastro.2009.12.052]

14 **Arsenault BJ**, Beaumont EP, Després JP, Larose E. Mapping body fat distribution: a key step towards the identification of the vulnerable patient? *Ann Med* 2012; **44**: 758-772 [PMID: 22149719 DOI: 10.3109/07853890.2011.605387]

15 **Preiss D**, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. *Clin Sci (Lond)* 2008; **115**: 141-150 [PMID: 18662168 DOI: 10.1042/CS20070402]

16 **Wong VW**, Chu WC, Wong GL, Chan RS, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Woo J, Chan FK, Chan HL. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. *Gut* 2012; **61**: 409-415 [DOI: 10.1136/gutjnl-2011-300342]

17 **Argo CK**, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. *Clin Liver Dis* 2009; **13**: 511-531 [PMID: 19818302 DOI: 10.1016/j.cld.2009.07.005]

18 **Starley BQ**, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. *Hepatology* 2010; **51**: 1820-1832 [PMID: 20432259 DOI: 10.1002/hep]

19 **Alisi A**, Manco M, Vania A, Nobili V. Pediatric nonalcoholic fatty liver disease in 2009. J Pediatr. 2009; 155: 469–447 [doi: 10.1016/j.jpeds.2009.06.014]

20 **Mencin AA**, Lavine JE. Nonalcoholic fatty liver disease in children. Curr *Opin Clin Nutr Metab Care* 2011; **14**: 151–157 [DOI: 10.1097/MCO.0b013e328342baec]

21 **Widhalm K**, Ghods E. Nonalcoholic fatty liver disease: achallenge for pediatricians. *Int J Obes* (Lond) 2010; **34**: 1451–1467 [PMID: 20838401 DOI: 10.1038/ijo.2010.185]

22 **Roberts EA**. Pediatric nonalcoholic fatty liver disease (NAFLD): a "growing" problem? *J Hepatol* 2007; **46**: 1133-1142 [PMID: 17445934 DOI: 10.1016/j.jhep.2007.03.003]

23 **Romeo S**, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* 2008; **40**: 1461-1465 [PMID: 18820647 DOI: 10.1038/ng.257]

24 **Schwimmer JB**, Celedon MA, Lavine JE, Salem R, Campbell N, Schork NJ, Shiehmorteza M, Yokoo T, Chavez A, Middleton MS, Sirlin CB. Heritability of nonalcoholic fatty liver disease. *Gastroenterology* 2009; **136**: 1585-1592 [PMID: 19208353 DOI: 10.1053/j.gastro.2009.01.050]

25 **Romeo S**, Huang-Doran I, Baroni MG, Kotronen A. Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. *Curr Opin Lipidol* 2010; **21**: 247-252 [PMID: 20480550 DOI: 10.1097/MOL.0b013e328338ca61]

26 **Deboer MD**. Ethnicity, obesity and the metabolic syndrome: implications on assessing risk and targeting intervention. *Expert Rev Endocrinol Metab* 2011; **6**: 279-289 [PMID: 21643518 DOI: 10.1586/eem.11.17]

27 **Kong AP**, Chow CC. Medical consequences of childhood obesity: a Hong Kong perspective. *Res Sports Med* 2010; **18**: 16-25 [PMID: 20391243 DOI: 10.1080/15438620903413107]

28 **Wong VW**, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. *Gut* 2010; **59**: 969-974 [PMID: 20581244 DOI: 10.1136/gut.2009.205088]

29 **Puppala J**, Siddapuram SP, Akka J, Munshi A. Genetics of nonalcoholic Fatty liver disease: an overview. *J Genet Genomics* 2013; **40** :15-22 [DOİ: 10.1016/j.jgg.2012.12.001]

30 **Carter-Kent C**, Yerian LM, Brunt EM, Angulo P, Kohli R, Ling SC, Xanthakos SA, Whitington PF, Charatcharoenwitthaya P, Yap J, Lopez R, McCullough AJ, Feldstein AE. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. *Hepatology* 2009; **50**: 1113-1120 [PMID: 19637190 DOI: 10.1002/hep.23133]

31 **Schwimmer JB**, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. *J Pediatr* 2003; **143**: 500-505 [PMID: 14571229 DOI: 10.1067/S0022-3476(03)00325-1]

32 **Manton ND**, Lipsett J, Moore DJ, Davidson GP, Bourne AJ, Couper RT. Non-alcoholic steatohepatitis in children and adolescents. *Med J Aust* 2000; **173**: 476-479 [PMID: 11149304]

33 **Navarro-Jarabo JM**, Ubiña-Aznar E, Tapia-Ceballos L, Ortiz-Cuevas C, Pérez-Aísa MA, Rivas-Ruiz F, Andrade RJ, Perea-Milla E. Hepatic steatosis and severity-related factors in obese children. *J Gastroenterol Hepatol* 2013; **28**: 1532-1538 [PMID: 23701491 DOI: 10.1111/jgh.12276]

34 **Willner IR**, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. *Am J Gastroenterol* 2001; **96**: 2957-2961 [PMID: 11693332 DOI: 10.1111/j.1572-0241.2001.04667.x]

35 **Rashid M**, Roberts EA. Nonalcoholic steatohepatitis in children. *J Pediatr Gastroenterol Nutr* 2000; **30**: 48-53 [PMID: 10630439 DOI: 10.1097/00005176-200001000-00017]

36 **Deboer MD**, Wiener RC, Barnes BH, Gurka MJ. Ethnic differences in the link between insulin resistance and elevated ALT. *Pediatrics* 2013; **132**: e718-726 [DOI: 10.1542/peds.2012-3584]

37 **Redgrave TG**. Formation of cholesteryl ester-rich particulate lipid during metabolism of chylomicrons. *J Clin Invest* 1970; **49**: 465-471 [PMID: 5415674 DOI: 10.1172/JCI106255]

38 **Tappy L**, Lê KA. Metabolic effects of fructose and the worldwide increase in obesity. *Physiol Rev* 2010; **90**: 23-46 [PMID: 20086073 DOI: 10.1152/physrev.00019.2009]

39 **Kusminski CM**, Shetty S, Orci L, Unger RH, Scherer PE. Diabetes and apoptosis: lipotoxicity. *Apoptosis* 2009; **14**: 1484-1495 [PMID: 19421860 DOI: 10.1007/s10495-009-0352-8]

40 **Unger RH**. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. *Endocrinology* 2003; **144**: 5159-5165 [PMID: 12960011 DOI: 10.1210/en.2003-0870]

41 **Ibrahim SH**, Kohli R, Gores GJ. Mechanisms of lipotoxicity in NAFLD and clinical implications. *J Pediatr Gastroenterol Nutr* 2011; **53**: 131-140 [PMID: 21629127 DOI: 10.1097/MPG.0b013e31822578db]

42 **Brown MS**, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. *Cell Metab* 2008; **7**: 95-96 [PMID: 18249166 DOI: 10.1016/j.cmet.2007.12.009]

43 **Della Corte C**, Alisi A, Saccari A, De Vito R, Vania A, Nobili V. Nonalcoholic fatty liver in children and adolescents: an overview. *J Adolesc Health* 2012; **51**: 305-312 [PMID: 22999829 DOI: 10.1016/j.jadohealth.2012.01.010]

44 **Nobili V**, Svegliati-Baroni G, Alisi A, Miele L, Valenti L, Vajro P. A 360-degree overview of paediatric NAFLD: recent insights. *J Hepatol* 2013; **58**: 1218-1229 [PMID: 23238106 DOI: 10.1016/j.jhep.2012.12.00]

45 **Samuel VT**, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. *J Biol Chem* 2004; **279**: 32345-32353 [PMID: 15166226]

46 **Tiniakos DG**, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. *Annu Rev Pathol* 2010; **5**: 145-171 [PMID: 20078219 DOI: 10.1146/annurev-pathol-121808-102132]

47 **Frasinariu OE**, Ceccarelli S, Alisi A, Moraru E, Nobili V. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. *Dig Liver Dis* 2013; **45**: 543-551 [PMID: 23280158 DOI: 10.1016/j.dld.2012.11.010]

48 **Nobili V**, Carpino G, Alisi A, Franchitto A, Alpini G, De Vito R, Onori P, Alvaro D, Gaudio E. Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. *Hepatology* 2012; **56**: 2142-2153 [PMID: 22467277 DOI: 10.1002/hep.25742]

49 **Marra F**, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. *Trends Mol Med* 2008; **14**: 72-81 [PMID: 18218340 DOI: 10.1016/j.molmed.2007.12.003]

50 **Verduci E**, Pozzato C, Banderali G, Radaelli G, Arrizza C, Rovere A, Riva E, Giovannini M. Changes of liver fat content and transaminases in obese children after 12-mo nutritional intervention. *World J Hepatol* 2013; **5**: 505-512 [DOI: 10.4254/wjh.v5.i9.505]

51 **Berardis S**, Sokal E. Pediatric non-alcoholic fatty liver disease: an increasing public health issue. *Eur J Pediatr* 2013; [Epub ahead of print] [PMID: 24068459 DOI: 10.1007/s00431-013-2157-6]

52 **Nobili V**, Cutrera R, Liccardo D, Pavone M, Devito R, Giorgio V, Verrillo E, Baviera G, Musso G. OSAS affects liver histology and inflammatory cell activation in paediatric NAFLD, regardless of obesity/insulin resistance. *Am J Respir Crit Care Med* 2013; [Epub ahead of print] [PMID: 24256086 DOI: 10.1164/rccm.201307-1339OC]

53 **Roberts EA**. Non-alcoholic fatty liver disease (NAFLD) in children. *Front Biosci* 2005; **10**: 2306-2318 [PMID: 15970496 DOI: 10.2741/1699]

54 **Ruhl CE**, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. *Gastroenterology* 2003; **124**: 71-79 [PMID: 12512031 DOI: 10.1053/gast.2003.50004]

55 **Sattar N**, Scherbakova O, Ford I, O'Reilly DS, Stanley A, Forrest E, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. *Diabetes* 2004; **53**: 2855-2860 [PMID: 15504965 DOI: 10.2337/diabetes.53.11.2855]

56 **Palekar NA**, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. *Liver Int* 2006; **26**: 151-156 [PMID: 16448452 DOI: 10.1111/j.1478-3231.2005.01209.x]

57 **Pacifico L**, Celestre M, Anania C, Paolantonio P, Chiesa C, Laghi A. MRI and ultrasound for hepatic fat quantification: relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease. *Acta Paediatr* 2007; **96**: 542-547 [PMID: 17306008 DOI: 10.1111/j.1651-2227.2007.00186.x]

58 **Radetti G**, Kleon W, Stuefer J, Pittschieler K. Non-alcoholic fatty liver disease in obese children evaluated by magnetic resonance imaging. *Acta Paediatr* 2006; **95**: 833-837 [PMID: 16801180 DOI: 10.1080/08035250500449890]

59 **Shimada M**, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishima M, Tsutsumi M, Takase S. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. *Am J Gastroenterol* 2007; **102**: 1931-1938 [PMID: 17511754 DOI:10.1111/j.1572-0241.2007.01322.x]

60 **Wong VW**, Hui AY, Tsang SW, Chan JL, Tse AM, Chan KF, So WY, Cheng AY, Ng WF, Wong GL, Sung JJ, Chan HL. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2006; **4**: 1154-1161 [PMID: 16904946 DOI: 10.1016/j.cgh.2006.06.011]

61 **Hui JM**, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? *Hepatology* 2004; **40**: 46-54 [PMID: 15239085 DOI: 10.1002/hep.20280]

62 **Bugianesi E**, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, Gentilcore E, Natale S, Cassader M, Rizzetto M, Pasquali R, Marchesini G. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. *J Clin Endocrinol Metab* 2005; **90**: 3498-3504 [PMID: 15797948 DOI: 10.1210/jc.2004-2240]

63 **Pagano C**, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, Sechi LA, Vettor R. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. *Eur J Endocrinol* 2005; **152**: 113-118 [PMID: 15762194 DOI: 10.1530/eje.1.01821]

64 **Aygun C**, Senturk O, Hulagu S, Uraz S, Celebi A, Konduk T, Mutlu B, Canturk Z. Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease. *Eur J Gastroenterol Hepatol* 2006; **18**: 175-180 [PMID: 16394799 DOI: 10.1097/00042737-200602000-00010]

65 **Louthan MV**, Barve S, McClain CJ, Joshi-Barve S. Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. *J Pediatr* 2005; **147**: 835-838 [PMID: 16356442 DOI: 10.1016/j.jpeds.2005.07.030]

66 **Zou CC**, Liang L, Hong F, Fu JF, Zhao ZY. Serum adiponectin, resistin levels and non-alcoholic fatty liver disease in obese children. *Endocr J* 2005; **52**: 519-524 [PMID: 16284427 DOI: 10.1507/endocrj.52.519]

67 **Musso G**, Gambino R, Biroli G, Carello M, Fagà E, Pacini G, De Michieli F, Cassader M, Durazzo M, Rizzetto M, Pagano G. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. *Am J Gastroenterol* 2005; **100**: 2438-2446 [PMID: 16279898 DOI: 10.1111/j.1572-0241.2005.00297.x]

68 **Sargin H**, Sargin M, Gozu H, Orcun A, Baloglu G, Ozisik M, Seker M, Uygur-Bayramicli O. Is adiponectin level a predictor of nonalcoholic fatty liver disease in nondiabetic male patients? *World J Gastroenterol* 2005; **11**: 5874-5877 [PMID: 16270401]

69 **Wong VW**, Hui AY, Tsang SW, Chan JL, Wong GL, Chan AW, So WY, Cheng AY, Tong PC, Chan FK, Sung JJ, Chan HL. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2006; **24**: 1215-1222 [PMID:17014580 DOI:10.1111/j.1365-2036.2006.03112.x]

70 **Crespo J**, Cayón A, Fernández-Gil P, Hernández-Guerra M, Mayorga M, Domínguez-Díez A, Fernández-Escalante JC, Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. *Hepatology* 2001; **34**: 1158-1163 [PMID: 11732005 DOI: 10.1053/jhep.2001.29628]

71 **Boyraz M**, Cekmez F, Karaoglu A, Cinaz P, Durak M, Bideci A. Serum adiponectin, leptin, resistin and RBP4 levels in obese and metabolic syndrome children with nonalcoholic fatty liver disease. *Biomark Med* 2013; **7**: 737-745 [PMID: 24044566 DOI: 10.2217/bmm.13.13]

72 **Castera L**, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. *Nat Rev Gastroenterol Hepatol* 2013; **10**: 666-675 [PMID: 24061203 DOI: 10.1038/nrgastro.2013.175]

73 **Joseph AE**, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. *Clin Radiol* 1991; **43**: 26-31 [PMID: 1999069 DOI: 10.1016/S0009-9260(05)80350-2]

74 **Shannon A**, Alkhouri N, Carter-Kent C, Monti L, Devito R, Lopez R, Feldstein AE, Nobili V. Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. *J Pediatr Gastroenterol Nutr* 2011; **53**: 190-195 [PMID: 21788761 DOI: 10.1097/MPG.0b013e31821b4b61]

75 **Johnson NA**, Walton DW, Sachinwalla T, Thompson CH, Smith K, Ruell PA, Stannard SR, George J. Noninvasive assessment of hepatic lipid composition: Advancing understanding and management of fatty liver disorders. *Hepatology* 2008; **47**: 1513-1523 [PMID: 18393289 DOI: 10.1002/hep.22220]

76 Pearce SG, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. *Biomark Res* 2013; **1**: 7 [PMID: 24252302 DOI: 10.1186/2050-7771-1-7]

77 **Wong GL**, Wong VW, Choi PC, Chan AW, Chum RH, Chan HK, Lau KK, Chim AM, Yiu KK, Chan FK, Sung JJ, Chan HL. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. *Clin Gastroenterol Hepatol* 2008; **6**: 1027-1035 [PMID: 18456573 DOI: 10.1016/j.cgh.2008.02.038]

78 **Wong VW**, Chan HL. Transient elastography. *J Gastroenterol Hepatol* 2010; **25**: 1726-1731 [PMID: 21039833 DOI: 10.1111/j.1440-1746.2010.06437.x.]

79 **Nobili V**, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista A, Fruhwirth R, Marcellini M, Pinzani M. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. *Hepatology* 2008; **48**: 442-448 [PMID: 18563842 DOI: 10.1002/hep.22376]

80 **Wong VW**, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, Choi PC, Kowo M, Chan AW, Merrouche W, Sung JJ, de Lédinghen V. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. *Hepatology* 2010; **51**: 454-462 [PMID: 20101745 DOI: 10.1002/hep.23312]

81 **Xanthakos SA**, Podberesky DJ, Serai SD, Miles L, King EC, Balistreri WF, Kohli R. Use of Magnetic Resonance Elastography to Assess Hepatic Fibrosis in Children with Chronic Liver Disease. *J Pediatr* 2013; [Epub ahead of print] [PMID: 24064151 DOI: 10.1016/j.jpeds.2013.07.050]

82 **Lee CK**, Perez-Atayde AR, Mitchell PD, Raza R, Afdhal NH, Jonas MM. Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience. *J Pediatr* 2013; **163**: 1058-64.e2 [PMID: 23759423 DOI: 10.1016/j.jpeds.2013.04.044]

83 **Shneider BL**, González-Peralta R, Roberts EA. Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD: Summary of a single topic conference. *Hepatology* 2006; **44**: 1344-1354 [PMID: 17058223 DOI: 10.1002/hep.21373]

84 **Eguchi A**, Povero D, Alkhouri N, Feldstein AE. Novel therapeutic targets for nonalcoholic fatty liver disease. *Expert Opin Ther Targets* 2013; **17**: 773-779 [PMID: 23600493 DOI: 10.1517/14728222.2013.789502]

85 **Musso G**, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. *Hepatology* 2010; **52**: 79-104 [PMID: 20578268 DOI: 10.1002/hep.23623]

86 **Bell LN,** Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA, Sanyal AJ, Kowdley KV, Neuschwander-Tetri BA, Brunt EM, McCullough AJ, Bass NM, Diehl AM, Unalp-Arida A, Chalasani N; Nonalcoholic Steatohepatitis Clinical Research Network. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: apioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholicsteatohepatitis trial follow-up study. *Hepatology* 2012; **56**: 1 311-1318 [DOI: 10.1002/hep.25805]

87 **Dufour JF**, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, Zala JF, Helbling B, Steuerwald M, Zimmermann A. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. *Clin Gastroenterol Hepatol* 2006; **4**: 1537-1543 [PMID: 17162245 DOI: 10.1016/j.cgh.2006.09.025]

88 **Malaguarnera M**, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, Avitabile T, Li Volti G, Galvano F. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial. *Am J Gastroenterol* 2010; **105**: 1338-1345 [PMID: 20068559 DOI: 10.1038/ajg.2009.719]

89 **Lavine JE**, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. *JAMA* 2011; **305**: 1659-1668 [PMID: 21521847 DOI: 10.1001/jama.2011.520]

90 **Ozcan U**, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Görgün CZ, Hotamisligil GS. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. *Science* 2006; **313**: 1137-1140 [PMID: 16931765 DOI: 10.1126/science.1128294]

91 **Clark JM**, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. *Gastroenterology* 2003; **124**: 248-250 [PMID: 12512048 DOI: 10.1053/gast.2003.50032]

92 **Wei Y**, Wang D, Topczewski F, Pagliassotti MJ. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. *Am J Physiol Endocrinol Metab* 2006; **291**: E275-E281 [PMID: 16492686 DOI: 10.1152/ajpendo.00644.2005]

93 **Akazawa Y**, Cazanave S, Mott JL, Elmi N, Bronk SF, Kohno S, Charlton MR, Gores GJ. Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. *J Hepatol* 2010; **52**: 586-593 [PMID: 20206402 DOI: 10.1016/j.jhep.2010.01.003]

94 **Listenberger LL**, Han X, Lewis SE, Cases S, Farese RV, Ory DS, Schaffer JE. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. *Proc Natl Acad Sci U S A* 2003; **100**: 3077-3082 [PMID: 12629214 DOI: 10.1073/pnas.0630588100]

95 **Cho T**, Kim YJ, Paik SS. The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease. *Pediatr Gastroenterol Hepatol Nutr* 2012; **15**: 256-265 [PMID: 24010096 DOI: 10.5223/pghn.2012.15.4.256]

96 **Oh MK**, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2008; **28**: 503-522 [PMID: 18532991 DOI: 10.1111/j.1365-2036.2008.03752.x.]

97 **Bozic MA**, Subbarao G, Molleston JP. Pediatric nonalcoholic fatty liver disease. *Nutr Clin Pract* 2013; **28**: 448-458 [PMID: 23917437 DOI: 10.1177/0884533613489153]

98 **Schwimmer JB**, Newton KP, Awai HI, Choi LJ, Garcia MA, Ellis LL, Vanderwall K, Fontanesi J. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2013; **38**: 1267-1277 [PMID: 24117728 DOI: 10.1111/apt.12518]

99 **Ramon-Krauel M**, Salsberg SL, Ebbeling CB, Voss SD, Mulkern RV, Apura MM, Cooke EA, Sarao K, Jonas MM, Ludwig DS. A low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children. *Child Obes* 2013; **9**: 252-260 [PMID: 23705885 DOI: 10.1089/chi.2013]

100 **Deldin AR**, Lee S. Role of physical activity in the treatment of nonalcoholic fatty liver disease in children and adolescents. *Appl Physiol Nutr Metab* 2013; **38**: 805-812 [PMID: 23855267 DOI: 10.1139/apnm-2012-0503]

101 **DeVore S**, Kohli R, Lake K, Nicholas L, Dietrich K, Balistreri WF, Xanthakos SA. A multidisciplinary clinical program is effective in stabilizing BMI and reducing transaminase levels in pediatric patients with NAFLD. *J Pediatr Gastroenterol Nutr* 2013; **57**: 119-123 [PMID: 23518484 DOI: 10.1097/MPG.0b013e318290d138]

**P- Reviewers: Liu EQ, Luo GH, Sonia R, Wong LH** **S- Editor:** Qi Y

**L- Editor: E- Editor:**